At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
External link for Illumina
BaseSpace Clarity LIMS is a laboratory information management system that helps genomics labs track samples and manage workflows for an optimized and efficient lab.
In Q1, we focused on building the infrastructure for the future of genomics. In Q2, we put that foundation to work, delivering measurable progress in multiomics, oncology, AI, and population genomics. Here’s how that progress took shape: 1️⃣ Accelerating multiomics growth The planned acquisition of SomaLogic accelerates Illumina’s proteomics business, advancing our multiomics strategy and positioning the company to achieve growth in a large, expanding market. 2️⃣ Expanding access to precision oncology With growing adoption of TSO Comprehensive, our clinical oncology portfolio continues to deliver high-performance insights, bringing biomarker testing closer to patients in every care setting. 3️⃣ Unlocking AI-powered insights for rare disease and oncology research We launched DRAGEN v4.4 driving the most accurate insights in variant calling, and unveiled PromoterAI, a first-of-its-kind algorithm that research shows may improve diagnostic yield for rare disease. Together with partners across the industry, we’re advancing the role of AI in genomic discovery. 4️⃣ Powering national genomics studies The Magic-I study in Ireland harnesses genomics and big data using Illumina sequencing and DRAGEN analysis, to optimize treatments in childhood cancers. It’s been a quarter of meaningful progress and momentum we’re carrying into the second half of 2025.
We're taking comprehensive genomic profiling to the next level. The new TruSight Oncology 500 v2 research assay adds built-in HRD biomarker detection powered by Myriad Genetics, faster turnaround times, and requires less tissue, helping labs accelerate access to critical insights for cancer therapy research. Learn more here ➡️ https://lnkd.in/gKsdePVn
At the San Diego Pride Parade, we joined employees, families, and friends to celebrate the community that surrounds and inspires us. 🌈 Every person at Illumina plays a role in advancing our mission to improve human health. We’re thankful to our team—and to iPride, one of our employee resource groups—for championing pride, inclusion, and connection year-round. It's in our DNA. Click through to see a few of our favorite moments. 🧡 #IlluminaProud
In the UK, students start making career decisions as young as 12 years old. For many, especially those with limited access to industry exposure and a variety of role models, finding a career path can be challenging. “You cannot be what you cannot see.” – Alison Coffey, Clinical Genomics Scientist at Illumina. That’s why we partnered with Form the Future CIC, a not-for-profit based in Cambridge, to help show students what’s possible. Through livestreamed genomics lessons, classroom DNA experiments, and honest job talks from our employees, students are getting a window into STEM careers and the people behind them. Learn more about the program: https://bit.ly/3IDKQQ1
With the help of Illumina Connected Multiomics and DRAGEN secondary analysis, it’s never been easier to accurately identify methylation events and genetic variants in the same reads with the Illumina 5-base solution: https://bit.ly/4d1Iq91
UofL Health is the first in the U.S. to offer patients TruSight™ Oncology (TSO) Comprehensive—the only FDA-approved test of its kind for solid tumors. This comprehensive assay delivers insights from a single tissue sample, helping care teams identify actionable mutations and guide patients toward targeted therapies or clinical trials. On-site testing enables more informed treatment decisions in less time. 🔗 Read more about how they're putting this into practice: https://bit.ly/40oZoZP
Ovarian cancer survivor Simone Lehwess Mozzilli dreams of a world where children diagnosed with cancer feel empowered. During her time at the hospital, the idea for her non-profit, Beaba, came to life: creating medical illustrations with clear, honest, and accessible language to help children understand procedures, communicate with doctors, and fight stigma. Eleven years in, Beaba’s signature resource, Beabook, includes 191 illustrated definitions and is available in over 300 hospitals worldwide. The impact is immeasurable, with dreams to grow their education efforts across all diseases: https://bit.ly/4lsWYC7
Everything we do at Illumina is anchored in our mission-driven culture of innovation, and that includes our focus on sustainability and employee experience. Together, our team is helping to shape the future of precision health while improving the health of the planet. Join us in celebrating these achievements: https://bit.ly/3GsCOc7
From advanced cancer care to emerging disease research, genomics is making an impact—and Illumina is at the center of it. During the American Society of Clinical Oncology (ASCO) Annual Meeting, Pratheesh Sathyan PhD, Head of AMR Oncology at Illumina, reflected on how our technology touches thousands of patients every day around the world—powered by 25+ years of genomics expertise. 🎥 Hear Pratheesh’s perspective from #ASCO25.